A NEW SOLUTION TO THE PROBLEM OF RECURRENT UROGENITAL CANDIDIASIS.

Mirsaidova A. Munisa Republican Specialized Scientific and Practical Medical Center for Dermatovenerology and Cosmetology, Tashkent, Uzbekistan, munisa876@mail.ru
Yulduz N. Radjabova Republican Specialized Scientific and Practical Medical Center for Dermatovenerology and Cosmetology, Tashkent, Uzbekistan, Corresponding Author Email ID: dr.radjabova@gmail.com
Shahnoza Z. Mavlyanova Republican Specialized Scientific and Practical Medical Center for Dermatovenerology and Cosmetology, Tashkent, Uzbekistan, shahnoza_m@mail.ru
Khilola Kh. Fayzieva Republican Specialized Scientific and Practical Medical Center for Dermatovenerology and Cosmetology, Tashkent, Uzbekistan, xfx.cosmetology1993@gmail.com

Abstract

AIM: We monitored 20 patients with recurrent urogenital candidiasis who received topical application of activated silica solution for rapid disease progression and prevention of recurrences. The purpose of our study is to improve the effectiveness of the treatment of urogenital candidiasis and reduce the number of relapses, given the local immune response. The problem is solved by the fact that in the developed method of treatment, which includes a comprehensive therapy (antimycotic drugs, vitamins, anti-inflammatory therapy), in addition locally in the form of sanations - vaginal irrigation is used activated silica solution.

Keywords:

recurrent urogenital candidiasis, activated silica solution, local immune response, yeast-like fungi.


Full Text:

PDF


References



1.Burmenskaya O.V. Molecular genetic markers of immune response in inflammatory diseases of the female reproductive system. Moscow. 2014; 249. VAK RF 03.03.03.03.Immunology 2. Amouri I, Sellami H, Borji N, Abbes S, Sellami A, Cheikhrouhou F, et al. Epidemiological survey of vulvovaginal candidiasis in Sfax, Tunisia. Mycoses. 2011;54:499–505. Gynecology. 2017; 03: 49-54 3. CDC. Sexually transmitted diseases treatment guidelines, 2010. MMWR. 2010;59(RR12):1-110. 4. Pogosyan SHM, Mezhevitinova EA, Abakarova PR, Donnikov AE, Muravyova VV. Profile of immune response gene expression in the vagina of women in the complex therapy of recurrent urogenital candidiasis. 5. Adane B. , Yeshiwork A. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. Bitew and Abebaw BMC Women's Health 2018;2-10 6. Olowe OA, Makanjuola OB, Olowe R, Adekanle DA. Prevalence of vulvovaginal candidiasis, trichomoniasis and bacterial vaginosis among pregnant women receiving antenatal care in Southwestern Nigeria. Eur J Microbiol Immunol. 2014;4:193–7. 7. Mavlyanov P.N., Ibragimov A.S. , Mavlyanov G.N., Maksudov M.R., Burhanov A.U. To the results of the study of the therapeutic properties of silicon-containing mineral waters of Uzbekistan // Collection of scientific papers of the conference: The impact of natural global changes and man-made conditions on hydrogeological, engineering-geological and geoecological processes: analysis of results and prediction of development". - Tashkent - 2018. - – с. 52-54.) 8. Semenukha K.V., Semenukha O.K. Urogenital candidiasis as a topical problem of modern girls. Dermatovenerology. Cosmetology. Sexopathology 2007;10:1-4 9.Aniebue UU, Nwankwo TO, Nwafor MI. Vulvovaginal candidiasis in reproductive age women in Enugu Nigeria, clinical versus laboratory-assisted diagnosis. Niger J Clin Pract 2018;21:1017-22. 10.Clemons, K. V., J. L. Spearow, R. Parmar, M. Espiritu, and D. A. Stevens. 11.Fan, S. R., X. P. Liu, and J. W. Li. 2008. Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of Candida species isolates among patients in southern China from 2003 to 2006. J. Obstet. Gynaecol. Res. 34:561–566. 12. Wuthrich M, Deepe GS, Klein B. Adaptive immunity to fungi. Annu Rev Immunol 2012; 30: 115-48. 13.Gaffen SL, Hernández-Santos N, Peterson AC. IL-17 signaling in host defense against Candida albicans. Immunol Res 2011; 50 (2-3): 181-7. 14. Amouri I, Sellami H, Abbes S, Hadrich I, Mahfoudh N, Makni H, et al. Microsatellite analysis of Candida isolates from recurrent vulvovaginal candidiasis. J Med Microb. 2012;61:1091–6. 15.Hernández-Santos N, Gaffen SL. Th17 cells in immunity to Candida albicans. Cell Host and Microbe 2012; 11 (5): 425-35. 16.Ilkit M, Guzel AB. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidiasis: a mycological perspective. Crit Rev Microbiol. 2011; 37:250–61. 17. Sung J, Kyeongju L, Bomi K, Hyun Ju You1,2,5 & GwangPyo K. Vaginal lactobacilli inhibit growth and hyphae formation of Candida albicans. Scientific Reports 2019; 9:8121 18.LeibundGut-Landmann S, Wüthrich M, Hohl TM. Immunity to fungi. Cur Opin Immunol 2012; 24 (4): 449-58. 19.Nnadi DC, Singh S. The prevalence of genital Candida species among pregnant women attending antenatal clinic in a tertiary health center in North-West Nigeria. Sahel Med J 2017;20:33-7. 20. Gladiator A, Wangler N, Trautwein-Weidner K, LeibundGut-Landmann S. Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection. J Immunol 2013; 190 (2): 521-5. 21.Sallusto F, Zielinski CE, Lanzavecchia A. Human Th17 subsets. Eur J Immunol 2012; 42 (9): 2215-20. 22. Kuchroo VK, Awasthi A. Emerging new roles of Th17 cells. Eur J Immunol 2012; 42 (9): 2211-4. 23.Unnikrishnan AG, Kalra S, Purandare V, Vasnawala H. Genital infections with sodium glucose cotransporter2 inhibitors: Occurrence and management in patients with Type 2 diabetes mellitus. Indian J Endocr Metab 2018;22:83742. 24. Fen Q., Quan W., Chunlian Z.. Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis. Infection and Drug Resistance. 2018;11:1893–1901 25. Cheng S-C, van de Veerdonk F, Smeekens S et al. Candida albicans dampens host defense by downregulating IL-17 production. J Immunol 2010;185(4):2450-7.

Refbacks

  • There are currently no refbacks.